Pelham Capital’s Moderna MRNA Stock Holding History

Pelham Capital’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-225,000	Closed	-$29.5M	–	17
2021 Q1	$29.5M	Buy	+225,000	New	+$32.6M	1.83%	12

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

LPC

Lone Pine Capital Greenwich, Connecticut $12.5B AUM 54.4% 1-Year Est. Return

Pelham Capital's MRNA Position: Q2 2021 in Review

Pelham Capital sold out of Moderna (MRNA) in Q2 2021, closing a stake of 225,000 shares — an estimated $29.5M sold.

Pelham Capital first reported a position in MRNA in Q1 2021 and held it in 1 quarter. The position peaked at $29.5M in Q1 2021. 903 funds tracked by Wall St. Rank hold MRNA as of Q2 2021.

Pelham Capital reported no remaining Moderna position as of Q2 2021 after selling out during the quarter.
Pelham Capital sold 225,000 Moderna shares in Q2 2021, an estimated $29.5M.
Pelham Capital first reported a position in Moderna in Q1 2021 and held it in 1 quarter.
Pelham Capital's Moderna position peaked at $29.5M in Q1 2021.
903 funds tracked by Wall St. Rank held Moderna as of Q2 2021.

Based on Pelham Capital's 13F filing for Q2 2021, filed 26 Jul 2021.